Literature DB >> 6304480

Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma.

G Hunsmann, N C Pedersen, G H Theilen, H Bayer.   

Abstract

The efficiency was examined of immunization with feline leukemia virus glycoprotein complexes (gp85 rosettes) to protect cats against tumors induced by feline sarcoma virus (FeSV). The glycoprotein was isolated from feline leukemia virus (FeLV). Young cats were vaccinated with the purified viral glycoprotein and challenged with FeSV (FeLV). FeLV gp85 antibody levels were measured by enzyme-linked immunosorbent assay and tumor volumes were determined. In immunized animals tumor development was reduced. Gp85 antibody levels before challenge were correlated inversely with tumor size (r2 = 0.79). This method appears to be suitable for fast and efficient testing of future FeLV vaccines.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6304480     DOI： 10.1007/bf02123497

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  17 in total

1.  Active and passive immunization of cats with inactivated feline oncornaviruses.

Authors:  J P Schaller; E A Hoover; R G Olsen
Journal:  J Natl Cancer Inst       Date:  1977-11       Impact factor: 13.506

2.  Studies of naturally transmitted feline leukemia virus infection.

Authors:  N C Pedersen; G Theilen; M A Keane; L Fairbanks; T Mason; B Orser; C H Che; C Allison
Journal:  Am J Vet Res       Date:  1977-10       Impact factor: 1.156

3.  Pathogenesis of feline viral fibrosarcomas: dose and age effects.

Authors:  S P Snyder; D L Dungworth
Journal:  J Natl Cancer Inst       Date:  1973-09       Impact factor: 13.506

4.  Experimental transmission of feline fibrosarcoma to cats and dogs.

Authors:  M B Gardner; R W Rongey; P Arnstein; J D Estes; P Sarma; R J Huebner; C G Rickard
Journal:  Nature       Date:  1970-05-30       Impact factor: 49.962

5.  Humoral immune reactivity to feline leukemia virus and associated antigens in cats naturally infected with feline leukemia virus.

Authors:  H Lutz; N Pedersen; J Higgins; U Hübscher; F A Troy; G H Theilen
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

6.  Envelope polypeptides of Friend leukemia virus: purification and structural analysis.

Authors:  J Schneider; H Falk; G Hunsmann
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

7.  ST feline sarcoma virus. Biological characteristics and in vitro propagation.

Authors:  P S Sarma; T Log; G H Theilen
Journal:  Proc Soc Exp Biol Med       Date:  1971-09

8.  A transmissible feline fibrosarcoma of viral origin.

Authors:  S K McDonough; S Larsen; R S Brodey; N D Stock; W D Hardy
Journal:  Cancer Res       Date:  1971-07       Impact factor: 12.701

9.  Safety and efficacy studies of live- and killed-feline leukemia virus vaccines.

Authors:  N C Pedersen; G H Theilen; L L Werner
Journal:  Am J Vet Res       Date:  1979-08       Impact factor: 1.156

10.  Vaccination against feline leukaemia virus using a cell membrane antigen system.

Authors:  W Jarrett; O Jarrett; L Mackey; H Laird; C Hood; D Hay
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396
View more
  5 in total

1.  Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.

Authors:  N C Pedersen; L Johnson; D Birch; G H Theilen
Journal:  Vet Immunol Immunopathol       Date:  1986-02       Impact factor: 2.046

2.  Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Authors:  W G Robey; L O Arthur; T J Matthews; A Langlois; T D Copeland; N W Lerche; S Oroszlan; D P Bolognesi; R V Gilden; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

3.  Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus.

Authors:  R L Dewar; V Natarajan; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

5.  Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.

Authors:  L O Arthur; S W Pyle; P L Nara; J W Bess; M A Gonda; J C Kelliher; R V Gilden; W G Robey; D P Bolognesi; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.